EPGN 696
Alternative Names: EPGN-696; LPA1R antagonist - Epigen Biosciences/Novo NordiskLatest Information Update: 28 Jun 2022
At a glance
- Originator Epigen Biosciences
- Developer Epigen Biosciences; Novo Nordisk
- Class Antifibrotics; Hepatoprotectants; Heterocyclic compounds; Small molecules; Urologics
- Mechanism of Action Lysophosphatidic acid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetic nephropathies; Idiopathic pulmonary fibrosis; Kidney disorders; Non-alcoholic steatohepatitis
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for preclinical development in Diabetic-nephropathies in USA (PO)
- 28 Jun 2022 No recent reports of development identified for preclinical development in Idiopathic-pulmonary-fibrosis in USA (PO)
- 28 Jun 2022 No recent reports of development identified for preclinical development in Kidney-disorders in USA (PO)